 |
|
|
| |
Efficacy and safety of doravirine-based regimens
by sex and race: long-term results from three phase 3 clinical trials
|
| |
| |
EACS 2023 Oct 18-21
Sharon L. Walmsley1*; Princy N. Kumar2; Chloe Orkin3; Melanie Thompson4; Kathleen Squires5;
Zhi Jin Xu5; Wayne Greaves5; Rebeca M. Plank5; Yohance Whiteside5; Rima Lahoulou6
1University Health Network, Toronto, ON, Canada; 2Georgetown University, Washington, DC, USA; 3Queen Mary University of London, London, United Kingdom; 4AIDS Research Consortium, Atlanta, GA, USA; 5Merck & Co., Inc., Rahway, NJ, USA; 6MSD France, Puteaux, France
*Presenting author
An employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, at the time of the study
|
| |
|
|
|
|
|
